EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Using Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies

Thomas C Beadnell iD, Susmita Jasti iD, Ruqi Wang iD, Bruce H Davis iD, Virginia Litwin iD

International Journal of Molecular Sciences · 24.09.2024 · 25 (19) · 10263

DOI: 10.3390/ijms251910263 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.09.2024. Verfasst von Thomas C Beadnell und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eurofins Viracor Biopharma, Lenexa, KS 66219, USA. Hauptthemen laut MEDLINE: Flow Cytometry, Clinical Trials as Topic, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monitoring chimeric antigen redirected (CAR) T-cells post-infusion in clinical trials is a specialized application of flow cytometry. Unlike the CAR T-cell monitoring for individual patients conducted in clinical laboratories, the data generated during a clinical trial will be used not only to monitor the therapeutic response of a single patient, but determine the success of the therapy itself, or even of an entire class of therapeutic compounds. The data, typically acquired at multiple testing laboratories, will be compiled into a single database. The data may also be used for mathematical modeling of cellular kinetics or to identify predictive biomarkers. With the expanded context of use, a robust, standardized assay is mandatory in order to generate a valuable and reliable data set. Hence, the requirements for assay validation, traceable calibration, technology transfer, cross-instrument standardization and regulatory compliance are high.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Flow CytometryClinical Trials as TopicImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumans

Stichwörter der Autor:innen

CAR T-cellCLSI H62NIST Flow Cytometry Standards Consortiumclinical trialimmunogenicityspectral flow cytometry

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Eurofins Viracor Biopharma, Lenexa, KS 66219, USA.
  • Eurofins Pharma Bioanalytical Services, St. Charles, MO 63304, USA.
  • Independent Researcher, Clifton, ME 04428, USA.
  • Eurofins Clinical Trial Solutions, Montreal, QC J2L 3N5, Canada.

ORCID-Profile: Thomas C Beadnell, Susmita Jasti, Ruqi Wang, Bruce H Davis, Virginia Litwin

Zitieren

APA

Beadnell, T. C., Jasti, S., Wang, R., Davis, B. H., & Litwin, V. (2024). Using Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies. International Journal of Molecular Sciences, 25(19), 10263. https://doi.org/10.3390/ijms251910263

Vancouver

Beadnell TC, Jasti S, Wang R, Davis BH, Litwin V. Using Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies. International Journal of Molecular Sciences. 2024;25(19):10263. doi:10.3390/ijms251910263

BibTeX
@article{Beadnell2024,
  author = {Beadnell, Thomas C and Jasti, Susmita and Wang, Ruqi and Davis, Bruce H and Litwin, Virginia},
  title = {Using Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {19},
  pages = {10263},
  doi = {10.3390/ijms251910263}
}
Kostenlos starten →